Last reviewed · How we verify
[14C]-GSK1278863 solution for IV infusion — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[14C]-GSK1278863 solution for IV infusion ([14C]-GSK1278863 solution for IV infusion) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [14C]-GSK1278863 solution for IV infusion TARGET | [14C]-GSK1278863 solution for IV infusion | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [14C]-GSK1278863 solution for IV infusion CI watch — RSS
- [14C]-GSK1278863 solution for IV infusion CI watch — Atom
- [14C]-GSK1278863 solution for IV infusion CI watch — JSON
- [14C]-GSK1278863 solution for IV infusion alone — RSS
Cite this brief
Drug Landscape (2026). [14C]-GSK1278863 solution for IV infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-gsk1278863-solution-for-iv-infusion. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab